重药控股公告，公司控股子公司重药股份以2.65亿元公开挂牌方式转让持有的化医财务公司20%股权， 受让方为重庆建峰工业集团有限公司。2025年12月9日，化医财务公司取得重庆市市场监督管理局换发 的营业执照，本次股权工商变更登记手续已办理完成。转让完成后，重药股份不再持有化医财务公司股 权。 ...

格隆汇12月10日丨南京医药(600713.SH)公布，公司控股子公司南京药业股份有限公司（简称"南京药 业"）之全资子公司南京鹤龄房产物业管理有限公司（简称"鹤龄房产物业公司"）、控股子公司南京鹤 龄药事服务有限公司（简称"鹤龄药事服务公司"）位于南京市雨花台区窑岗村33、35号的两处房产土地 进行依法征收，涉及土地使用权面积34,709.49㎡，房屋建筑面积20,644.33㎡，合计补偿金额2.94亿元。 ...

2024年1至12月份，南京医药的营业收入构成为：批发占比94.72%，零售占比4.53%，电商占比0.48%， 其他业务占比0.24%，第三方物流占比0.03%。 每经头条（nbdtoutiao）——白金信用卡权益大缩水：贵宾厅限次、酒店减量⋯⋯银行吐槽没赚头，"羊 毛党"薅了个寂寞 每经AI快讯，南京医药（SH 600713，收盘价：5.31元）12月10日晚间发布公告称，公司第十届董事会 临时会议于2025年12月9日以通讯方式召开。会议审议了《关于政府征收公司二级子公司部分房产土地 的议案》等文件。 截至发稿，南京医药市值为70亿元。 （记者 王晓波） ...

科源制药（301281.SZ）12月10日在投资者互动平台表示，尊敬的投资者您好，公司在海南投资设有子 公司海南林恒药业有限公司，主要业务为医药商业代理及配送服务，是公司在下游产业链的延伸。感谢 您的关注。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵司在海南省是否有子公司？是否在海南省有相 关业务布局？ ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医药商业板块主力资金净流出1.74亿元，游资资金净流出1.05亿元，散户资金 净流入2.79亿元。医药商业板块个股资金流向见下表： 证券之星消息，12月10日医药商业板块较上一交易日上涨0.71%，重药控股领涨。当日上证指数报收于 3900.5，下跌0.23%。深证成指报收于13316.42，上涨0.29%。医药商业板块个股涨跌见下表： ...

证券日报网讯12月10日，嘉事堂（002462）在互动平台回答投资者提问时表示，公司始终坚持做好主营 业务，提升经营质量，努力为投资者创造良好回报。 ...

Group 1 - The pharmaceutical commercial sector experienced a short-term decline, with Ruikang Pharmaceutical falling over 7% [1] - Other companies such as Runda Medical, Renmin Tongtai, Saili Medical, and Luyan Pharmaceutical also saw declines [1]

格隆汇12月10日丨嘉事堂(002462.SZ)在投资者互动平台表示，公司目前有胸腺肽、免疫球蛋白等相关 药品的销售业务。 ...

Meeting Attendance and Voting - The shareholder meeting was held on December 9, 2025, at the specified location in Beijing [2] - A total of 778 shareholders and proxies attended the meeting, representing 464,351,992 shares [1][2] - The voting method complied with the Company Law and Articles of Association, with both on-site and online voting conducted [2] Board Meeting Details - The board meeting had 9 directors present, including 4 independent directors, and was chaired by Liu Yuetao [7] - The meeting was convened following proper notification procedures, and all attendees were qualified to participate [4][7] Resolutions Passed - The board approved the adjustment of the specialized committee members with a unanimous vote of 9 in favor [9] - The board also approved an increase in the estimated amount for daily related transactions for 2025, amounting to 85,302.36 million yuan, with independent directors abstaining from the vote [9][15] - The board confirmed the operating performance assessment for 2024, based on audited financial data [10][11] Legal Verification - The meeting was witnessed by Beijing Guofeng Law Firm, which confirmed that the meeting's procedures complied with legal and regulatory requirements [4] Daily Related Transactions - The company plans to increase the estimated amount for daily related transactions for 2025, which is necessary for its operational needs and does not harm the interests of non-related shareholders [14][15] - The total expected amount for new daily related transactions is 85,302.36 million yuan, and the pricing policies are aligned with market principles [16][18]

Group 1 - "*ST Suwu" (600200) has received a decision from the Shanghai Stock Exchange to terminate its stock listing, effective December 1, 2025, with a trading period for delisting starting on December 9, 2025, lasting for 15 trading days [1] - The Shanghai Stock Exchange will implement strict measures against abnormal trading behaviors related to the aforementioned stocks, which may include monitoring accounts, suspending trading, and restricting account activities [2] - "HeFu China" (603122) has experienced significant stock price fluctuations, with its stock price deviating sharply from its fundamentals, indicating potential risks of market overreaction and irrational speculation [1][2] Group 2 - "Haiwang Biological" (000078) has shown signs of impulsive trading behavior, prompting the Shenzhen Stock Exchange to take notice [2]